Related Experiment Video
Updated: Jun 12, 2026
06:37
Immunolabelling Myofiber Degeneration in Muscle Biopsies
Published on: December 5, 2019
Aging with muscular dystrophy: pathophysiology and clinical management
Gregory T Carter1, Michael D Weiss, Joel R Chamberlain
1Department of Rehabilitation Medicine, University of Washington School of Medicine, Box 356490, Seattle, WA 98195, USA. gtcarter@uw.edu <gtcarter@uw.edu>
Summary
Advances in medical science and technology improve quality of life and longevity for muscular dystrophy (MD) patients. A comprehensive approach enhances care and meets evolving patient expectations for aging with MD.
Area of Science:
- Medical Science
- Physiology
- Molecular Genetics
- Biomedical Engineering
- Computer Science
Background:
- Muscular dystrophy (MD) presents unique challenges for patients, impacting quality of life and lifespan.
- Technological and scientific progress offers new possibilities for managing MD.
- Aging patient populations with MD have evolving needs and expectations.
Purpose of the Study:
- To review the impact of recent scientific and technological advances on the management of muscular dystrophy.
- To explore strategies for improving the quality of life for aging individuals with MD.
- To emphasize the importance of a comprehensive medical and rehabilitative approach.
Main Methods:
- Review of recent advances in relevant scientific and engineering fields.
- Analysis of the impact of these advances on patient care and outcomes.
- Discussion of comprehensive management strategies for aging MD patients.
Main Results:
- Significant improvements in functional equipment and assistive technologies for MD patients.
- Increased longevity observed in individuals with MD due to medical advancements.
- Enhanced patient expectations regarding quality of life and care.
Conclusions:
- Multidisciplinary medical and rehabilitative care is crucial for aging MD patients.
- Addressing patient expectations is key to enhancing their quality of life.
- Continued integration of technological and scientific progress can further improve outcomes for individuals with MD.
Related Concept Videos
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...